INS and cancer: First, reduced blood insulin concentrations at the cancer cell membrane results in less binding to the insulin receptor with resulting downstream inhibition of the PI3K-Akt-mTOR (PAM) signaling cascade [23], as well as the RAS-RAF-MEK-ERK pathway [24].